Abstract
We assessed effect of therapy with HMG--CoA reductase inhibitor rosuvastatin on the number of circulating hemopoietic stem CD34+, CD133+ cells in peripheral blood of patients with systolic left ventricular dysfunction of ischemic genesis. Number of circulating hemopoietic stem CD34+, CD133+ cells in patients with chronic heart failure did not differ from their number in control group, however we revealed tendency to increase of number of endothelial CD34+, CD133+, VEGFR-2+ progenitor cells. We confirmed presence of relationship between quantity of circulating stem and progenitor cells and traditional risk factors of cardiovascular events: age, excessive body mass, arterial hypertension, and intima media thickness of common carotid arteries. Besides lipid lowering effect therapy with rosuvastatin was associated with lowering of C-reactive protein level and increase of number of circulating CD34+, CD133+ cells.
MeSH terms
-
AC133 Antigen
-
Adult
-
Antigens, CD / blood
-
Antigens, CD34 / blood
-
Dose-Response Relationship, Drug
-
Endothelium, Vascular / drug effects
-
Endothelium, Vascular / immunology
-
Endothelium, Vascular / pathology*
-
Female
-
Fluorobenzenes / administration & dosage*
-
Follow-Up Studies
-
Glycoproteins / blood
-
Heart Failure / blood*
-
Heart Failure / drug therapy
-
Heart Failure / physiopathology
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
-
Male
-
Mesenchymal Stem Cells / drug effects
-
Mesenchymal Stem Cells / immunology
-
Mesenchymal Stem Cells / pathology*
-
Middle Aged
-
Peptides / blood
-
Pyrimidines / administration & dosage*
-
Rosuvastatin Calcium
-
Stroke Volume / physiology
-
Sulfonamides / administration & dosage*
-
Treatment Outcome
Substances
-
AC133 Antigen
-
Antigens, CD
-
Antigens, CD34
-
Fluorobenzenes
-
Glycoproteins
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
PROM1 protein, human
-
Peptides
-
Pyrimidines
-
Sulfonamides
-
Rosuvastatin Calcium